GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori.
In an attempt to examine the influence of the type of GnRH analogue used during controlled ovarian hyperstimulation on IVF outcome in patients with an unfavorable outcome a priori, we studied 728 consecutive cycles in patients with repeated IVF failure. In patients with repeated failure, the GnRH agonist group showed significantly higher clinical pregnancy rate compared with the GnRH antagonist group (20.8% vs 14.5%).
Orvieto
Raoul
R
Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel. raoulo@barzi.health.gov.il
Homburg
Roy
R
Meltcer
Simion
S
Rabinson
Jacob
J
Anteby
Eyal Y
EY
Scharf
Shimon
S
D000328:Adult; D004967:Estrogens / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000819:agonists* / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006801:Humans; D054315:Oocyte Retrieval / Q000379:methods*; D010062:Ovulation Induction / Q000379:methods*; D017060:Patient Satisfaction; D011247:Pregnancy; D018873:Pregnancy Rate; D011379:Prognosis; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
D004967:Estrogens; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; C062876:cetrorelix